Madrigal Pharmaceuticals licenses SYH2086 to enhance MASH treatment, combining it with Rezdiffra for improved patient outcomes.
Quiver AI Summary
Madrigal Pharmaceuticals has announced a global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist aimed at developing combination treatments for metabolic dysfunction-associated steatohepatitis (MASH), utilizing Madrigal's existing therapy, Rezdiffra™ (resmetirom). The collaboration aims to enhance treatment efficacy for MASH by combining Rezdiffra’s benefits with SYH2086’s weight loss effects in a single daily pill. Madrigal intends to initiate clinical development of SYH2086 in early 2026, following an upfront payment of $120 million to CSPC, with additional milestone payments potentially reaching $2 billion. Both companies believe this partnership will help address the critical needs of MASH patients, as the disease is a leading cause of liver transplantation and associated health risks.
Potential Positives
- Exclusive global license agreement with CSPC strengthens Madrigal's pipeline strategy for developing innovative combination treatments for MASH.
- Potential for a best-in-class oral treatment for MASH highlighted by the combination of Rezdiffra and SYH2086.
- Planned initiation of clinical development for SYH2086 in the first half of 2026 indicates proactive steps in expanding treatment options for patients.
- Reinforcement of Madrigal's market position as a leader in MASH treatments through strategic partnerships and pipeline developments.
Potential Negatives
- Entering into a licensing agreement with CSPC requires Madrigal to make a substantial upfront payment of $120 million, which could strain financial resources, especially if further funding is needed for ongoing operations.
- The potential for up to $2 billion in milestone payments tied to the development and commercialization of SYH2086 raises concerns regarding the company's financial commitments and risks associated with meeting these milestones.
- The press release includes a detailed mention of risks and uncertainties related to the company's clinical trials and financial condition, highlighting past operating losses and potential challenges in achieving profitability, which could undermine investor confidence.
FAQ
What is the purpose of the license agreement between Madrigal and CSPC?
The agreement aims to support Madrigal's development of combination treatments for MASH, leveraging SYH2086 alongside Rezdiffra™.
What is SYH2086 in the context of this announcement?
SYH2086 is a preclinical oral GLP-1 receptor agonist licensed from CSPC, designed to enhance treatment for MASH when combined with Rezdiffra.
When will clinical development for SYH2086 start?
Madrigal plans to initiate clinical development for SYH2086 in the first half of 2026.
What are the financial terms of the agreement?
CSPC receives a $120 million upfront payment and may earn up to $2 billion in milestone payments and royalties.
How does Rezdiffra™ help in treating MASH?
Rezdiffra is approved for MASH and works by targeting key underlying causes, optimizing efficacy, and balancing weight loss benefits.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDGL Insider Trading Activity
$MDGL insiders have traded $MDGL stock on the open market 57 times in the past 6 months. Of those trades, 0 have been purchases and 57 have been sales.
Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:
- PAUL A FRIEDMAN has made 0 purchases and 10 sales selling 30,276 shares for an estimated $10,688,888.
- REBECCA TAUB has made 0 purchases and 10 sales selling 30,101 shares for an estimated $10,628,103.
- ROBERT E. WALTERMIRE (Senior VP, Chief Pharma Dev.) has made 0 purchases and 11 sales selling 15,340 shares for an estimated $5,235,591.
- FRED B CRAVES has made 0 purchases and 13 sales selling 15,470 shares for an estimated $5,082,479.
- MARDI DIER (SVP and CFO) has made 0 purchases and 3 sales selling 2,219 shares for an estimated $720,592.
- CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 9 sales selling 1,834 shares for an estimated $597,839.
- SHANNON T KELLEY (General Counsel) sold 415 shares for an estimated $139,025
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDGL Hedge Fund Activity
We have seen 162 institutional investors add shares of $MDGL stock to their portfolio, and 135 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HOLOCENE ADVISORS, LP added 390,545 shares (+inf%) to their portfolio in Q1 2025, for an estimated $129,360,220
- FMR LLC removed 215,751 shares (-24.9%) from their portfolio in Q1 2025, for an estimated $71,463,203
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 171,649 shares (+860.0%) to their portfolio in Q1 2025, for an estimated $56,855,298
- MORGAN STANLEY added 166,347 shares (+76.1%) to their portfolio in Q1 2025, for an estimated $55,099,116
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 126,320 shares (+773.9%) to their portfolio in Q1 2025, for an estimated $41,840,973
- SIREN, L.L.C. removed 125,942 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $41,715,768
- HOOD RIVER CAPITAL MANAGEMENT LLC added 116,155 shares (+90.9%) to their portfolio in Q1 2025, for an estimated $38,474,020
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDGL Analyst Ratings
Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 05/02/2025
- B. Riley Securities issued a "Buy" rating on 05/02/2025
- Canaccord Genuity issued a "Buy" rating on 05/02/2025
- JMP Securities issued a "Market Outperform" rating on 04/24/2025
- Citigroup issued a "Buy" rating on 02/27/2025
- HC Wainwright & Co. issued a "Buy" rating on 02/27/2025
To track analyst ratings and price targets for $MDGL, check out Quiver Quantitative's $MDGL forecast page.
$MDGL Price Targets
Multiple analysts have issued price targets for $MDGL recently. We have seen 6 analysts offer price targets for $MDGL in the last 6 months, with a median target of $450.5.
Here are some recent targets:
- Eliana Merle from UBS set a target price of $458.0 on 05/02/2025
- Mayank Mamtani from B. Riley Securities set a target price of $460.0 on 05/02/2025
- Edward Nash from Canaccord Genuity set a target price of $420.0 on 05/02/2025
- Jonathan Wolleben from JMP Securities set a target price of $443.0 on 04/24/2025
- David Lebovitz from Citigroup set a target price of $469.0 on 02/27/2025
- Ed Arce from HC Wainwright & Co. set a target price of $405.0 on 02/27/2025
Full Release
- License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom)
- Combining Rezdiffra with the oral GLP-1, SYH2086, offers potential for a best-in-class MASH treatment in a once-a-day, well-tolerated pill
CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.
“We’ve made remarkable progress this year advancing our strategic priorities – from the continued successful launch of Rezdiffra, to securing new IP protection through 2044, to laying the groundwork for Rezdiffra’s next stages of growth in F4c and Europe,” said Bill Sibold, Chief Executive Officer of Madrigal. “This agreement to acquire global rights to SYH2086 aligns perfectly with our long-term goal to extend our leadership in MASH by building a pipeline anchored by Rezdiffra. We believe a combination of Rezdiffra and SYH2086 has the potential to deliver a best-in-class oral treatment for patients with MASH.”
David Soergel, M.D., Chief Medical Officer of Madrigal, added, “The clinical rationale for developing a combination therapy with Rezdiffra and an oral GLP-1 is clear: we want to optimize efficacy and tolerability in MASH by balancing the weight loss from a GLP-1 with the fibrosis and lipid reduction of Rezdiffra in a once-a-day pill. In the pivotal Phase 3 MAESTRO-NASH trial, even modest weight loss of five percent or more enhanced Rezdiffra’s antifibrotic benefit, so we are confident that combination therapy with SYH2086 has the potential to provide increased efficacy for patients with MASH.”
“We are pleased to announce the in-license of our oral GLP-1 by Madrigal, an innovative company that pioneered the first approved treatment for MASH,” said Dongchen Cai, Chairman of the Board, CSPC. “We believe Madrigal’s strong clinical development and commercial capabilities will help unlock the full potential of SYH2086 to benefit patients.”
Financial Considerations
Under the agreement, CSPC has granted Madrigal an exclusive global license to develop, manufacture, and commercialize SYH2086. CSPC will receive an upfront payment of $120 million and is eligible to receive up to $2 billion in milestone payments if certain development, regulatory and commercial milestones are achieved, as well as royalties on net sales. CSPC may develop and commercialize other oral GLP-1 agonists in China subject to certain conditions. The transaction is anticipated to close in the fourth quarter of 2025, subject to the applicable regulatory clearance.
About CSPC Pharmaceutical Group’s SYH2086
SYH2086, a preclinical candidate developed by the CSPC with complete global intellectual property rights, is a novel oral small molecule GLP-1 receptor agonist. GLP-1 receptor agonists are a class of drugs that exert their effects through the GLP-1 receptor and have been developed as treatments for the management of type 2 diabetes and obesity. Their core mechanisms of action include enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite, thereby offering both glycemic control and weight loss benefits. Preclinical data demonstrated that SYH2086 exhibited excellent in vitro agonistic activity as well as in vivo glucose-lowering and weight-loss effects, with a linear pharmacokinetic (PK) profile over a wide dose range across multiple animal species, with no significant safety risks observed.
About MASH
Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, need for liver transplantation, and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S., and the fastest-growing indication for liver transplantation in Europe.
Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10-17 times higher risk of liver-related mortality as compared to patients without fibrosis. Those who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.
As MASH disease awareness improves and disease prevalence increases, the number of diagnosed patients with MASH with moderate to advanced fibrosis or compensated MASH cirrhosis (F2-F4c) is expected to grow.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit
www.madrigalpharma.com
.
Forward-Looking Statement
This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to Madrigal’s expected development timelines for SYH2086, the potential benefit of SYH2086 in combination with Rezdiffra, the anticipated timeline to close the licensing transaction and Madrigal’s leadership position in the MASH sector. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; risks related to the parties ability to close the transaction in a timely manner or at all; risks associated with development of early stage candidates; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; our history of operating losses and the possibility that we may never achieve or maintain profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to Madrigal’s ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action; market demand for and acceptance of Rezdiffra; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financing on acceptable terms; our ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitive trials; future topline data timing or results; our ability to prevent and/or mitigate cyber-attacks; the timing and outcomes of clinical trials of Rezdiffra (resmetirom); the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to our business and our ability to comply with such laws and regulations. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s submissions filed with the U.S. Securities and Exchange Commission(“SEC”), for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 26, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.
Madrigal Pharmaceuticals, Inc.
Investor Contact
Tina Ventura,
[email protected]
Media Contact
Christopher Frates,
[email protected]